All News

Experts weigh in on valuable findings that can be gleaned despite the fact that the phase III trial did not generate clinically meaningful results.

The highest rates of excess body weight–associated cancer were found in the South and Midwest, Alaska, and the District of Columbia, according to the study.

Cancer Network spoke with Tracy D. Vannorsdall, PhD and Patricia Ganz, MD about treatment methods for cancer-related cognitive impairment.

Cancer Network spoke with Dr. Chuan-Hsiang Huang about his lab’s research on Ras-ERK protein interactions within cancer cells.

Cancer Network spoke with Dr. Rachel Karchin about the contemporary search for cancer-driving gene mutations.

A study shows patients in the placebo group of clinical trials testing against targeted and immunotherapy cancer drugs may experience a high rate of grade 3/4 adverse events.

The authors of a European review provide recommendations for all stakeholders on smooth implementation of cancer biosimilar agents.

Can expanded use of oncology biosimilar agents and supportive care agents help support the CMS' value-based care efforts?

Cancer Network speaks with Dr. Pavel Sumazin about his ongoing efforts to further understand how lncRNA influence genes with known function in cancers.

Cancer Network speaks with Eduardo Eyras, PhD about the emerging roles of RNA splicing variants in cancer treatment.

Researchers evaluated the efficacy of 5-florouracil vs imiquimod in preventing site-specific keratinocyte carcinoma.

Researchers in England investigated whether risk for suicide was elevated in cancer patients, and which cancer types might have the greatest risk.

Erin McMenamin, CRNP, of Penn Medicine, discusses how oral side effects affect head and neck cancer patients.

Cancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.

Survey results published in JAMA Network Open looked at motivating factors behind patient travel and how far they were willing to go for treatment.

Gary H. Lyman, MD, MPH, says the plan does not address several significant concerns, such as delay tactics that limit prompt access to biosimilars.

Guy Ben-Betzalel, MD spoke with Cancer Network about the emerging role of targeted BRAF+MEK inhibition in antitumor immunity.

Professor Lana E. Kandalaft, PharmD, PhD spoke with Cancer Network about the next generation of cancer immunotherapy.

A recent study in JAMA Oncology examined the average daily cost of biosimilar filgrastim-sndz compared with the brand name biologic.

Stephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.

This article discusses some of the popular diets that cancer patients pursue, and the positive and negative aspects associated with these diets.

A study in Thyroid evaluated the safety and efficacy of concurrent intensity-modulated radiation therapy and doxorubicin in thyroid cancer.

We spoke with Erin McMenamin, CRNP, of Penn Medicine, about the recent study on opioid switching in cancer patients.

Interim results are in from a study evaluating whether adding selumetinib to RAI improves complete response, irrespective of MAPK pathway alterations.

We spoke with Kelly Hogan, MS, RD, about the recent JAMA study on the association between organic food consumption and cancer risk.

The findings of this study, recently published in JAMA Oncology, directly contradict previously conducted research on the same topic.

Oncologists now have some clarification on the use of moderate hypofractionation and ultrahypofractionation from ASTRO, ASCO, and the AUA.

Dr. Denise Faustman spoke with Cancer Network about TNFR2 and its emerging role in understanding regulatory T-cell behavior.

Dr. William Newman spoke with Cancer Network about the roles of epigenetic silencing in heritable cancer syndromes.